Assessing the potential cost effectiveness of pneumococcal vaccines in the US. Methodological issues and current evidence

Drugs and Aging

Volumn 15, Issue SUPPL. 1, 1999, Pages 31-36

  Hutton, John ^a,b   Iglesias, Cynthia ^a,b   Jefferson, Tom O ^b  

^a MEDTAP International Inc   (United Kingdom)

^b UK COCHRANE CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; ELDERLY CARE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STREPTOCOCCUS INFECTION; UNITED STATES;

EID: 0033372232     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915001-00004     Document Type: Article

References (18)

1. Institute of Medicine. New vaccine development: establishing priorities. Diseases of importance in developing countries. Vol. 2, Washington DC: National Academy Press, 1985: 44-62
2. Leowski J. Mortality from acute respiratory infections in children under five years of age: global estimates. World Health Stat 1986; 39: 138-44
3. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998; 352: 1295-302
4. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. BMJ 1996; 312: 1521-5
5. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80
6. Drummond MF, Jefferson TO for the BMJ Working Party on guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. BMJ 1996; 313: 275-83
7. Sisk J, Riegelman R. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104: 79-86
8. Gable CB, Botteman M, Savage G, et al. The cost-effectiveness of pneumococcal vaccination strategies. Pharmacoeconomics 1997; 12: 161-74
9. Jimenez FJ, Guallar P, Rubio C, et al. Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Br J Med Econ 1996; 10: 193-202
10. Willems JS, Sanders CR, Riddiough MA, et al. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303 (10): 553-9
11. Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981; 245: 473-7
12. Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990; 264: 2910-5
13. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcai vaccination of HIV-infecled patients: a policy analysis. Am J Med 1993; 94: 160-8
14. Sisk J, Moskowitz AJ, Whang W. Cost effectiveness of vaccination against pneumococcal pneumonia among elderly people. JAMA 1997; 278: 1333-9
15. Fine M, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77
16. Hutchison BG, Oxman AD, Lloyd S. et al. Clinical effectiveness of pneumococcal vaccine: a meta-analysis. Department of Clinical Epidemiology and Biostatistics, MacMaster University, Hamilton, Ontario, 1995
17. Hutchison BG, Oxman AD, Lloyd S. Comprehensives and bias in reporting clinical trials. Study of reviews of pneumococcal vaccine effectiveness. Can Fam Physician 1995; 41: 1356-60
18. Jefferson TO. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. Vaccine 1998; 16: 1487-95